Lundbeck's stock has been in a constant down-trend since the former CEO left in favour of becoming CEO at Teva Pharmaceuticals. Though the stock seems to be - technically speaking - showing its first signs to break the long-term down-trend. The RSI trying to break into the zone above 50 (signalising more buyers than sellers), combined with the MacD indicator, which is breaking the SMA for the second in a short period of time. This indicates the needed momentum to continue upwards.
Looking at the stock fundamentally, we see that more and more banks and investment funds are changing the attitude towards the company from "sell" to "buy". This is due to the fact that the company's stock has over the last year decreased by 27% relative to the markets general increase.
Looking at the stock fundamentally, we see that more and more banks and investment funds are changing the attitude towards the company from "sell" to "buy". This is due to the fact that the company's stock has over the last year decreased by 27% relative to the markets general increase.